momelotinib
Trade name: Ojjaara
Small moleculeapprovedOrphan Drug FDA
Approved
Sep 15, 2023
Momelotinib, sold under the brand name Ojjaara among others, is an anticancer medication used for the treatment of myelofibrosis. It is a Janus kinase inhibitor and it is taken by mouth. — Wikipedia
Clinical trial activity
23 trials · 17 clinical orgs · 1 marketing orgs
Phase 1
8
Phase 2
17
Phase 3
4
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT00935987)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
2010s
2020s
- Sep 15, 2023
GlaxoSmithKline — Earliest FDA Approval
- Sep 15, 2023
GlaxoSmithKline — Marketing Organization
- Sep 15, 2023
GlaxoSmithKline — NDA Organization
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Fibrosis · Phase 2
- Leukemia, Myeloid · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Early Phase 1
- Leukemia, Neutrophilic, Chronic · Early Phase 1
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Polycythemia Vera · Phase 3
- Primary Myelofibrosis · Phase 3
- Thrombocythemia, Essential · Phase 2
- Thrombocytopenia · Phase 2
- Transplants · Phase 1
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Approval history
- approvedSep 15, 2023
Chemistry & pharmacology
Loading structure…
SMILES
N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1- Mol. weight
- 414.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1078178 ↗
- WikipediaMomelotinib ↗
- ChEMBLCHEMBL2219411 ↗
Also known as
- cyt-11387
- cyt-11387
- cyt387
- cyt387
- cyt387
- cyt 387
- cyt-387
- cyt-387
- cyt-387
- gs-0387
- gs-0387
- momelotinib
- momelotinib
- momelotinib
- momelotinib
- momelotinib
- momelotinib dihydrochloride
- momelotinib dihydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07104799 | Phase 1 | Jan 31, 2026 | GlaxoSmithKline, Harvard University |
| NCT07071155 | Early Phase 1 (Phase 1) | Dec 5, 2025 | Johns Hopkins University |
| NCT07098936 | Phase 2 | Oct 31, 2025 | GlaxoSmithKline, Groupe Francophone des Myelodysplasies |
| NCT06847867 | Phase 2 | Apr 7, 2025 | GlaxoSmithKline |
| NCT06517875 | Phase 2 | Dec 17, 2024 | GlaxoSmithKline |
| NCT06235801 | Phase 1/Phase 2 (Phase 2) | May 22, 2024 | GlaxoSmithKline, University of Texas at Houston |
| NCT05980806 | Phase 2 | Mar 31, 2024 | Karyopharm Therapeutics Inc |
| NCT04173494 | Phase 3 | Nov 30, 2019 | Sierra Oncology, Inc., University of Texas at Houston |
| NCT03441113 | Phase 2 | May 3, 2018 | Gilead Sciences |
| NCT02515630 | Phase 2 | Jan 29, 2016 | Gilead Sciences |
| NCT02258607 | Phase 1 | Mar 11, 2015 | Gilead Sciences |
| NCT02244489 | Phase 1 | Nov 5, 2014 | Gilead Sciences |
| NCT02206763 | Phase 1 | Oct 16, 2014 | Gilead Sciences |
| NCT02251821 | Phase 2 | Oct 1, 2014 | National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), University of Washington |
| NCT02101268 | Phase 3 | Jun 19, 2014 | Gilead Sciences |
| NCT02101021 | Phase 3 | Jun 2, 2014 | Gilead Sciences |
| NCT02124746 | Phase 2 | Apr 30, 2014 | Gilead Sciences |
| NCT01998828 | Phase 2 | Feb 1, 2014 | Gilead Sciences |
| NCT01969838 | Phase 3 | Dec 6, 2013 | Gilead Sciences |
| NCT01423058 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Gilead Sciences, YM Biosciences |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 13 | 13 | 3 | 2009 |
| GlaxoSmithKline | For profit | 6 | 3 | 3 | 2024 |
| Harvard University | Academic/Hospital | 2 | 1 | 2 | 2009 |
| Mayo Clinic | Academic/Hospital | 2 | 0 | 1 | 2009 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 2 | 2019 |
| Groupe Francophone des Myelodysplasies | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Karyopharm Therapeutics Inc | For profit | 1 | 1 | 1 | 2024 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Melbourne Health | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2014 |
| Sierra Oncology, Inc. | For profit | 1 | 1 | 1 | 2019 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2014 |
| YM Biosciences | For profit | 1 | 0 | 1 | 2011 |
17 organizations
Page 1 / 1
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | MKTG | Sep 15, 2023 |
| GlaxoSmithKline | For profit | SYN | Sep 15, 2023 |
| GlaxoSmithKline | For profit | NDA | Sep 15, 2023 |